Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.
The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The South San Francisco, California-based company was founded by Dennis Lo to use noninvasive methods for early detection of cancer and other diseases.
The company has been working with NGS-based ctDNA testing for some time in research, but has now made its first move into the clinical sphere.
The company has been working with pharmaceutical companies to support clinical trials and drug development with its unique combined DNA and RNA liquid biopsy platform.
Results from a study have spurred a new prospective trial comparing arrays, sequencing, and several single-marker assays in men receiving hormonal therapies.
A University of Toronto team developed the probes to improve upon its previously described electrochemical clamp assay technology.
Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.
A study by researchers in Austria suggests read depth patterns upstream of transcription start sites can provide clues to gene expression.
Last month, the foundation, in partnership with the Washington State Department of Health, released seven educational videos about prenatal testing.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.